Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¾Ç¼º±³Á¾È¯ÀÚ¿¡¼­ ¾çÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µÀ» ÀÌ¿ëÇÑ Á¾¾çÀç¹ß°ú ¹æ»ç¼±±«»ç¿ÍÀÇ °¨º° Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence in Patients with Malignant Gliomas Using 18F-FDG Positron Emission Tomography

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1997³â 26±Ç 2È£ p.165 ~ 172
Á¤Èñ¿ø, À̱¤È£, ±èµ¿±Ô,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Èñ¿ø (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

À̱¤È£ (  ) 
°æ»ó´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç
±èµ¿±Ô (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°úÇб³½Ç

Abstract

¼­ ·Ð
½Å°æ±³Á¾Àº ÁÖÀ§ÀÇ Á¤»ó ³ú Á¶Á÷°úÀÇ °æ°è°¡ ºÒ¸íÈ®ÇÏ¿© ¼ö¼úÀûÀ¸·Î ¿ÏÀüÁ¦°Å°¡ ¾î·Æ°í
Á¾¾ç³»¿¡¼­ ºÎÀ§¿¡ µû¶ó ¾Ç¼ºµµÀÇ Â÷À̸¦ º¸ÀÌ´Â °æ¿ì°¡ ¸¹À¸¸ç ½Ã°£°æ°ú¿¡ µû¶ó ¾Ç¼ºº¯È­
¸¦ ÀÏÀ¸Å³ ¼ö Àֱ⠶§¹®¿¡ Ä¡·á¿¡ ¸¹Àº ¾î·Á¿òÀÌ ÀÖ´Ù. µû¶ó¼­ ½Å°æ±³Á¾ÀÇ Ä¡·á¿¡ ÀÖ¾î ¸ð
¼¼Æ÷¾ç ¼º»ó¼¼Æ÷Á¾(pilocytic astrocytoma)ÀÇ °æ¿ì¸¦ Á¦¿ÜÇÏ°í´Â ¼ö¼úÀû Ä¡·á¸¸À¸·Î ¿ÏÄ¡¸¦
±â´ëÇϱâ Èûµé¸ç ƯÈ÷ ¾Ç¼ºÀÇ °æ¿ì ´ë°³ ¹æ»ç¼± Ä¡·á¿Í Ç×¾ÏÁ¦ Åõ¿©¸¦ º´ÇàÇÏ°Ô µÈ´Ù. ¹æ»ç
¼± Ä¡·á´Â À°¾ÈÀ¸·Î ½Äº°ÇÒ ¼ö ¾ø¾î ¼ö¼úÈÄ¿¡µµ Á¾¾ç°ú Á¤»ó ³úÁ¶Á÷ »çÀÌ¿¡ ³²°ÔµÇ´Â Á¾¾ç
¼¼Æ÷ÀÇ Ä¡·á¸¦ À§Çؼ­ »Ó ¸¸ ¾Æ´Ï¶ó Á¾¾ç¼¼Æ÷ÀÇ ¾Ç¼º º¯È­¸¦ ¾ïÁ¦Çϱâ À§ÇÏ¿© ½ÃÇàµÇ´Â º¸
Á¶¼ö´ÜÀÌ´Ù ±×·¯³ª ¹æ»ç¼± Ä¡·áÀÇ °¡Àå ½É°¢ÇÑ ÇÕº´ÁõÀº ¹æ»ç¼± ±«»ç·Î¼­ ¹æ»ç¼± Ä¡·á ÈÄ
¼ö°³¿ù¿¡¼­ ¼ö³â»çÀÌ¿¡ ¹ß»ýÇϱ⠶§¹®¿¡ ¹æ»ç¼±±«»ç ¹ß»ý½Ã Á¤È®ÇÑ Áø´ÜÀ¸·Î Á¾¾çÀç¹ß°ú °¨
º°ÇÏ¿© Ä¡·á¹æħÀ» °áÁ¤ÇÏ°í ȯÀÚÀÇ ¿¹Èĸ¦ °áÁ¤ÇÏ´Â °ÍÀº ¸Å¿ì Áß¿äÇÏ´Ù°í ÇÏ°Ú´Ù. ¹æ»ç¼±
±«»ç´Â computerized tomography(CT)³ª magnetic resonance image(MRI)¿Í °°Àº ¹æ»ç¼±ÇÐ
Àû°Ë»ç·Î´Â °¨º°Áø´ÜÀÌ ºÒ°¡´ÉÇÏ¸ç º´¸® Á¶Á÷ÇÐÀû ¼Ò°ß¸¸ÀÌ È®Áø ¹æ¹ýÀÌ´Ù. ±×·¯³ª ÃÖ±Ù ¾ç
ÀüÀÚ¹æÃâ ´ÜÃþÃÔ¿µ(positron emission tomography)(PET)°¡ µµÀÔµÈ ÈÄ Á¶Á÷ÀÇ ´ë»ç¸¦ ÃøÁ¤
ÇÒ ¼ö ÀÖ°ÔµÇ¾î ºñħ½ÀÀûÀ¸·Î Á¾¾çÀç¹ß°ú ¹æ»ç¼±±«»çÀÇ °¨º°ÀÌ °¡´ÉÇÏ°Ô µÇ¾ú´Ù. ±¹³»¿¡¼­
´Â º» º´¿ø¿¡¼­ óÀ½À¸·Î 1995³âºÎÅÍ ÀÓ»ó°Ë»ç¸¦ ½ÃÇàÇÏ°í ÀÖ¾î ¾ÆÁ÷±îÁö PET¿Í °ü·ÃµÈ
¿¬±¸´Â ¹ÌÈíÇÑ »óÅÂÀÌ´Ù ¿Ü±¹¿¡¼­´Â ³úÇ÷°ü Áúȯ ¹× ³úÁ¾¾çÇÑÀÚ¿¡¼­ È°¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ
°í Àִµ¥ ±× Áß fluorine-18-fluorodeoxyglucose(18F-FDG)´Â ³úÁ¾¾çÀÇ ¼ö¼ú
¹× ¹æ»ç¼± Ä¡·á ÈÄ¿¡ ¹ß»ýÇÏ´Â ¹æ»ç¼±±«»ç(radiation necrosis)¿Í Á¾¾çÀç¹ß°£ÀÇ °¨º°Áø´Ü¿¡
¸¹ÀÌ ÀÌ¿ëµÇ°í ÀÖ´Ù.
Á¾¾çÀç¹ß°ú ¹æ»ç¼±±«»ç¿ÍÀÇ °¨º°Áø´Ü¿¡ À־ 18F-FDG PETÀÇ Á¤È®µµ¿¡
°üÇؼ­´Â ¾ÆÁ÷±îÁö ³í¶õÀÌ ÀÖÀ¸³ª ÀÌ¿Í °ü·ÃµÈ ¿¬±¸´Â ±¹³»¿¡¼­ ¾ÆÁ÷ º¸°íµÈ ¹Ù°¡ ¾ø´Ù.
ÀúÀÚµéÀº ³ú±³Á¾È¯ÀÚ¿¡¼­ ¼ö¼ú°ú ¹æ»ç¼±Ä¡·á ÈÄ¿¡ ¹ß»ýÇÏ´Â ¹æ»ç¼±±«»ç¿Í Á¾¾çÀÇ Àç¹ßÀ»
°¨º°Çϴµ¥ À־ 18F-FDG PETÀÇ À¯¿ëµµ¸¦ ±Ô¸íÇÏ°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
#ÃÊ·Ï#
The authors evaluated the usefulness of the positron emission tomographs(FET) with
fluorine-18-fluorodeoxyglucose(18-FDG) in diagnosing tumor recurrence
and differentiating it from radiation necrosis following external beam irradiation of
malignant glilomas Patients were studied from the time they had first exhibited either
clinical or radiological deterioration after an initial period of posttreatment stabilization
Ten studies were performed in ten patients, and 18F-FDG uptake by the
lesion was then compared to uptake by adjacent normal gray matter
Four of ten cases demonstrated newly entranced lesions on magnetic resonance
imaging(MRI) and hypermetabolic foci in the PET examinations All of these patients
were diagnosed as tumor recurrence either clinically or histolocally, during follow up
period of the patients' progress The remaining six Gases had newly enhanced lesions on
MRI and hypometablic foci in the PET studies ; five of them were diagnosed as
radiation necrosis, but one lesion(0.8 cm In diameter) was diagnosed Clinically as a
tumor recurrence The overall accuracy o1 the PET study in differentiation the tumor
recurrence from radiation necrosis was 90% and the sensitivity for detection of
recurrence 80%.
The authors conclude that the PET study with 18F-FDG is useful in
differentiating the tumor recurrence from radiation necrosis in patients with malignant
glioma and could be used to select the group of patients who may have benefits from
antitumor therapy.

Å°¿öµå

18F-FDG PET; Recurrence; Radiation necrosis; Malignant glioma.;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS